Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

OMEGA INTERVENTIONAL PAIN PLLC

NPI: 1417253907 · SALT LAKE CITY, UT 84106 · Pain Medicine (Anesthesiology) Physician · NPI assigned 02/01/2011

$667K
Total Medicaid Paid
14,839
Total Claims
12,857
Beneficiaries
8
Codes Billed
2018-01
First Month
2024-11
Last Month

Provider Details

Authorized OfficialPULLEY, STEVEN (OWNER)
NPI Enumeration Date02/01/2011

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 1,646 $36K
2019 2,665 $116K
2020 2,108 $82K
2021 2,869 $140K
2022 2,599 $130K
2023 1,866 $99K
2024 1,086 $63K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 10,694 9,228 $480K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 1,107 1,038 $60K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1,055 825 $59K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 684 663 $45K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 556 490 $17K
27096 42 37 $3K
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg 656 535 $1K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 45 41 $1K